Literature DB >> 11909001

Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders.

Claire Larroche1, Youri Chanseaud, Paloma Garcia de la Pena-Lefebvre, Luc Mouthon.   

Abstract

Intravenous immunoglobulins (IVIg) are therapeutic preparations of normal human immunoglobulin (Ig) G obtained from pools of blood from more than 1000 healthy donors, and exert immunomodulatory effects in autoantibody-mediated and T-cell-mediated autoimmune disorders and systemic inflammatory diseases. IVIg mechanisms of action in autoimmune diseases have been extensively analysed during the last 15 years and include the following: (i) interaction of the IgG Fc fragment with Fc receptors on leucocytes and endothelial cells; (ii) interaction of infused IgG with complement proteins; (iii) monocyte and lymphocyte modulation of synthesis and release of cytokines and cytokine antagonists; (iv) modulation of cell proliferation and reparation; (v) neutralisation of circulating autoantibodies; (vi) selection of immune repertoires; and (vii) interaction with other cell-surface molecules on T and B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11909001     DOI: 10.2165/00063030-200216010-00005

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  3 in total

Review 1.  Intravenous immunoglobulin and multiple sclerosis.

Authors:  Anat Achiron; Shmuel Miron
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases.

Authors:  D Peterlana; A Puccetti; S Simeoni; E Tinazzi; R Corrocher; C Lunardi
Journal:  Clin Rheumatol       Date:  2004-07-14       Impact factor: 2.980

3.  Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.

Authors:  Katrin Kofler; Anke Strölin; Vanessa Geiger; Lukas Kofler
Journal:  J Cutan Med Surg       Date:  2021-03-28       Impact factor: 2.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.